Comparing the current results to its competitors, Viridian Therapeutics Inc reported Revenue increase in the 1 quarter 2026 by 95.83 % year on year. The sales growth was above Viridian Therapeutics Inc 's competitors' average revenue growth of 10.08 %, achieved in the same quarter.
Viridian Therapeutics Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 2.41 %
Viridian Therapeutics Inc 's Comment on Competition and Industry Peers
The biotechnology and pharmaceutical industries are characterized by rapid changes and intense competition in developing new technologies and proprietary products. The company's product candidates target multiple markets and will compete based on the diseases addressed and marketing authorizations obtained. Competitors include other companies, such as Amgen, which has greater resources and expertise. Amgen's Tepezza is the only FDA-approved medication for Thyroid Eye Disease (TED), with other therapies like corticosteroids used off-label for TED symptoms. Amgen is also developing an on-body subcutaneous formulation of Tepezza.
December 16, 2024
As December 16, 2024 approaches, all eyes will be on Viridian Therapeutics, Inc. (NASDAQ: VRDN) as the biopharmaceutical company prepares to unveil the topline results from its THRIVE-2 Phase 3 clinical trial evaluating its promising product, veligrotug, for the treatment of chronic Thyroid Eye Disease (TED). This pivotal moment represents a crucial juncture for Viridian, as success in this trial could significantly bolster the company’s position in the competitive landscape of rare disease therapies.The December 16 conference call and webcast is likely to be met with a blend of anticipation and uncertainty. Analysts and investors are keenly aware that the outcome of the THRIVE-2 trial could dictate not on...
July 3, 2024
Viridian Therapeutics Induces Grants to Attract Top Talent and Drive InnovationIn a recent press release, Viridian Therapeutics, a leading biopharmaceutical company specializing in the discovery and development of breakthrough medicines for serious and rare diseases, announced its approval of inducement grants under Nasdaq Listing Rule 5635(c)(4). These grants include non-qualified stock options, aiming to attract and retain talented individuals who can contribute to the company s growth and success.The decision to grant non-qualified stock options was made by a majority of the independent directors serving on the Compensation Committee of Viridian s Board of Directors. This strategic move demonstrates Virid...
Publicly Traded Peers of Viridian Therapeutics Inc
Amgen Inc Share Performance
+54.15%
One Year
Amgen Inc
Profile
Amgen Inc.s business model focuses on leveraging advanced biotechnology to create therapeutic products for various diseases, particularly in the fields of oncology, inflammation, and cardiovascular health. The company invests heavily in research and development to drive innovation, while also utilizing strategic partnerships and acquisitions to enhance its product pipeline. Additionally, Amgen emphasizes a strong global commercial presence to maximize the accessibility and impact of its therapeutics in the healthcare market.
Regeneron Pharmaceuticals Inc operates a business model centered on the discovery and commercialization of cutting-edge biopharmaceuticals, particularly in the fields of ophthalmology, oncology, immunology, and rare diseases. They leverage their strong research and development capabilities, including their proprietary technologies, to create innovative therapies that address unmet medical needs. Additionally, Regeneron forms strategic collaborations and partnerships to enhance their development pipeline and expand market access for their products.
Incyte Corporation is a biopharmaceutical company that primarily focuses on the research, development, and commercialization of innovative medicines targeting oncology and serious inflammatory conditions. Their business model emphasizes robust R&D investments to discover potential drug candidates, often engaging in collaborations with other organizations to enhance their development capabilities. Incyte leverages its extensive intellectual property portfolio to protect and maximize the value of its therapeutic advancements in the market.
Immunovant Inc is a biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases by leveraging their expertise in research and development, clinical trials, and regulatory approvals. Their business model revolves around discovering innovative treatments, conducting rigorous testing, and seeking regulatory clearance to bring their products to market and improve patient outcomes.
Eyepoint Pharmaceuticals Inc is a pharmaceutical company that operates on a specialty business model focused on advancing ophthalmic therapies. They develop and commercialize innovative treatments using their proprietary drug delivery technology, allowing for sustained release of drugs to the eye. By leveraging their expertise in ophthalmology and controlled release technology, Eyepoint aims to improve patient outcomes and address unmet medical needs in eye care.
Sources:
Viridian Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Viridian Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
